

CLAIMS

1. A composition for use in treating cancer, wherein the composition comprises an antibody that binds to CD47 or an antigen-binding fragment thereof comprising a variable heavy chain (VH) CDR1 comprising SEQ ID NO: 50, a VH CDR2 comprising SEQ ID NO: 72, a VH CDR3 sequence comprising SEQ ID NO: 52, a variable light chain (VL) CDR1 comprising SEQ ID NO: 53, a VL CDR2 comprising SEQ ID NO: 71, and a VL CDR3 comprising SEQ ID NO: 55, wherein the composition is to be administered in combination with rituximab, wherein the administration of rituximab to the subject results in B cell depletion and a reduction in immune response in the subject to the antibody that binds to CD47 or an antigen-binding fragment thereof.
2. The composition for use of claim 1, wherein the antibody or antigen-binding fragment thereof comprises a VH comprising a sequence selected from the group consisting of SEQ ID NOs: 6 and 11.
3. The composition for use of claim 1 or 2, wherein the antibody or antigen-binding fragment thereof comprises a VL comprising a sequence selected from the group consisting of SEQ ID NOs: 42 and 46.
4. The composition for use of any one of claims 1 to 3, wherein the antibody or antigen-binding fragment thereof is an IgG isotype selected from the group consisting of IgG1 isotype, IgG2 isotype, IgG3 isotype, and IgG4 isotype.
5. The composition for use of any one of claims 1 to 3, wherein the antibody or antigen-binding fragment thereof is an IgG isotype selected from IgG4P and IgG4PE.
6. The composition for use of any one of claims 1 to 5, wherein the composition is a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
7. The composition for use of any one of claims 1 to 6, wherein the antibody or antigen-binding fragment thereof is to be administered to the subject at a dose of 0.3, 1, 2, 4, 8, 15, or 20 mg/kg.

8. The composition for use of any one of claims 1 to 7, wherein the rituximab is to be administered to the subject at a dose of 300, 325, 350, 375, 400, 425, 450, or 500 mg/m².
9. The composition for use of any one of claims 1 to 8, wherein the composition further comprises another anti-cancer agent.
10. The composition for use of any one of claims 1 to 9, wherein the cancer is a hematological cancer.
11. The composition for use of claim 10, wherein the hematological cancer is multiple myeloma, non-Hodgkin's lymphoma, or acute myeloid leukemia (AML).
12. The composition for use of any one of claims 1 to 11, wherein the composition is not to be administered with a proteasome inhibitor to the subject.
13. The composition for use of claim 12, wherein the composition is not to be administered with bortezomib to the subject.
14. The composition for use of any one of claims 1 to 13, wherein the composition for use is not to be administered with methotrexate to the subject.